Uric Acid and Colorectal Cancer: An Emerging Predictive Biomarker

David S. Klein, MD FACA FACPM
Jan 25
5 min read

Uric acid has traditionally been viewed through a narrow clinical lens, largely confined to gout and nephrolithiasis. In recent years, however, it has become increasingly clear that uric acid functions as a broader metabolic and inflammatory signal, with relevance to cardiovascular disease, insulin resistance, and potentially cancer risk¹⁻³.

Among malignancies of interest, colorectal cancer stands out. A growing body of epidemiologic and mechanistic data suggests that elevated serum uric acid may function as a predictive index, reflecting biological conditions that promote colorectal carcinogenesis years before clinical disease becomes apparent⁴⁻⁶.

Illustration showing how elevated uric acid reflects metabolic inflammation, gut dysfunction, and oxidative stress linked to increased colorectal cancer risk. — Uric Acid and Colorectal Cancer Risk

What Is Uric Acid?

Uric acid is the final metabolic product of purine degradation in humans. Purines arise from endogenous cellular turnover and dietary sources such as red meat, organ meats, alcohol, and fructose-containing foods⁷.

Under physiologic conditions, uric acid circulates in plasma and is excreted primarily by the kidneys. When production exceeds renal and intestinal excretion, serum levels rise.

Biologically, uric acid plays a dual role: it functions as an extracellular antioxidant, yet once transported intracellularly, it promotes oxidative stress, mitochondrial dysfunction, and pro-inflammatory signaling⁸⁻¹⁰.

Uric Acid as a Marker of Metabolic Stress

Elevated uric acid is strongly associated with:

Insulin resistance
Metabolic syndrome
Central adiposity
Hypertension
Chronic low-grade inflammation¹¹⁻¹³

These same conditions are independently linked to increased colorectal cancer risk. Rather than acting as a single causative agent, uric acid likely reflects a metabolically permissive environment characterized by oxidative stress, altered glucose metabolism, immune dysregulation, and impaired cellular repair mechanisms.

Inflammation, Oxidative Stress, and Colorectal Carcinogenesis

Chronic inflammation is a well-established driver of colorectal cancer. Elevated uric acid has been shown to:

Activate NF-κB and inflammasome pathways
Increase reactive oxygen species within epithelial cells
Promote endothelial dysfunction and microvascular impairment
Influence immune cell behavior within the tumor microenvironment¹⁴⁻¹⁶

Over time, these processes may facilitate DNA damage, impaired apoptosis, and dysregulated cellular proliferation within colonic tissue.

Epidemiologic Evidence Linking Uric Acid and Colorectal Cancer

Large observational cohorts have demonstrated a positive association between higher serum uric acid levels and colorectal cancer incidence, particularly in men and individuals with features of metabolic syndrome⁴⁻⁶,¹⁷.

Notably, in several studies this association persisted after adjustment for age, BMI, smoking, diabetes, and renal function, suggesting uric acid may provide independent prognostic information rather than acting solely as a confounder.

Importantly, elevated uric acid often precedes diagnosis by many years, supporting its potential role as an early risk stratification marker rather than a marker of established malignancy.

The Role of Cologuard® in Average-Risk Screening

Visual overview of colorectal cancer screening for average-risk adults, showing how stool DNA testing, colonoscopy, and healthy lifestyle choices work together to reduce risk. — Colorectal cancer screening and prevention overview

For individuals at average risk for colorectal cancer, stool-based screening with Cologuard® represents a validated, noninvasive screening option¹⁸⁻²⁰. Cologuard combines fecal immunochemical testing (FIT) with molecular detection of altered DNA markers associated with colorectal neoplasia. While it does not replace colonoscopy, it has demonstrated high sensitivity for colorectal cancer and clinically meaningful sensitivity for advanced adenomas. In patients with metabolic risk factors or elevated inflammatory markers,

Cologuard may improve screening adherence and serve as a practical entry point into guideline-based colorectal cancer prevention, with positive results appropriately followed by diagnostic colonoscopy.

Clinical Implications for Preventive Medicine

Uric acid offers several advantages as a clinical signal:

Widely available and inexpensive
Routinely measured
Reflects modifiable metabolic processes
Integrates nutrition, insulin signaling, renal handling, and inflammation

Its greatest value lies in contextual interpretation, alongside insulin, triglycerides, hs-CRP, ferritin, waist circumference, and family history.

What This Means for Patients

An elevated uric acid level does not diagnose colorectal cancer. It does suggest that metabolic and inflammatory conditions associated with increased cancer risk may be present.

Addressing uric acid often overlaps with established colorectal cancer risk-reduction strategies:

Improving insulin sensitivity
Reducing fructose and ultra-processed foods
Optimizing body composition
Supporting gut health
Reducing systemic inflammation

In this way, uric acid becomes a preventive signal, prompting earlier intervention rather than delayed detection.

A Measured Perspective

Uric acid should not be viewed as a standalone cancer test. Its clinical relevance lies in pattern recognition over time, particularly when combined with other metabolic and inflammatory markers.

As preventive medicine moves toward biology-driven risk assessment, uric acid may represent an underutilized, clinically accessible indicator of colorectal cancer susceptibility—already present in routine laboratory data.

REFERENCES

Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-1821.https://pubmed.ncbi.nlm.nih.gov/18946066/
Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62(10):3307-3315.https://pubmed.ncbi.nlm.nih.gov/24065788/
Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-1741.https://pubmed.ncbi.nlm.nih.gov/26136212/
Strasak AM, Rapp K, Hilbe W, et al. Serum uric acid and risk of cancer mortality. Am J Epidemiol. 2007;166(5):651-657.https://pubmed.ncbi.nlm.nih.gov/17609496/
Lee J, Hong YS, Park SH, et al. Serum uric acid and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2471-2478.https://pubmed.ncbi.nlm.nih.gov/20826820/
You YN, Chen Z, Zhang C, et al. Hyperuricemia and colorectal cancer risk: A cohort study. BMC Cancer. 2021;21:1133.https://pubmed.ncbi.nlm.nih.gov/34736584/
Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.https://pubmed.ncbi.nlm.nih.gov/16204163/
Sautin YY, Johnson RJ. Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):608-619.https://pubmed.ncbi.nlm.nih.gov/18600514/
Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99(11):759-766.https://pubmed.ncbi.nlm.nih.gov/23349459/
Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis. J Biol Chem. 2012;287(48):40732-40744.https://pubmed.ncbi.nlm.nih.gov/23035112/
Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and metabolic syndrome. Circulation. 2007;115(19):2526-2532.https://pubmed.ncbi.nlm.nih.gov/17470699/
Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism. Kidney Int. 2005;68(2):642-650.https://pubmed.ncbi.nlm.nih.gov/16014044/
Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression. Hypertension. 2005;46(4):932-937.https://pubmed.ncbi.nlm.nih.gov/16144982/
Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature. 2006;440(7081):237-241.https://pubmed.ncbi.nlm.nih.gov/16407889/
Zamarron BF, Chen W. Dual roles of uric acid in cancer. Clin Transl Oncol. 2021;23(6):1022-1032.https://pubmed.ncbi.nlm.nih.gov/33225333/
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.https://pubmed.ncbi.nlm.nih.gov/20303878/
Li J, Wang Y, Huang X, et al. Hyperuricemia and cancer incidence. Sci Rep. 2016;6:25655.https://pubmed.ncbi.nlm.nih.gov/27166916/
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.https://pubmed.ncbi.nlm.nih.gov/24645800/
Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for colorectal cancer screening. Ann Intern Med. 2016;165(10):673-682.https://pubmed.ncbi.nlm.nih.gov/27618636/
Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening. Am J Gastroenterol. 2021;116(3):458-479.https://pubmed.ncbi.nlm.nih.gov/33591341/

The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances.

Subscribe to our Blog